Loading
1 insider purchase totalling €466k over the last 90 days, the latest filed 10 Aug 2026.
Citi Pharma Ltd. is a listed company. Filings by its managers are published through PSX (SECP). In the past year (25 October 2025 to 25 October 2026), 22 filings came from 0 insiders.
The record shows 15 purchases on the open market worth €2.2M, made by 0 insiders, against 4 sales worth €999k by 0 insiders. The net balance comes to €1.2M on the buying side. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. The largest single trade was a sale of €526k, published on 30 January 2026.
The clock since the last published purchase (10 August 2026) now reads 76 days. Between a trade and the moment it shows up on PSX (SECP), the median delay is 3 days. This delay matters because a trade only becomes useful information once it is public.
Compared with its exchange (281 companies, median 3 filings), a count of 22 filings is above the norm. Looking back to 2023, when coverage begins, insiders filed 16 purchases and 5 sales.
Every figure here comes from the filings published by PSX (SECP) and describes the past, not future prices; it is not investment advice.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
· cache
25 of 31 declarations
Citi Pharma Ltd. is a company specialized in the pharmaceutical sector, operating in the XKAR market.